Articles On Adalta (ASX:1AD)

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

  Highlights Early trade tone led by discretionary names and financials, with broader strength across technology and resources. Small caps expand into new e-commerce channels and formalise fresh licensing arrangements across aud...

 Advances on research and development tax incentives are proving a popular source of ancillary financing Audeara shares surge up to 36% on China deal Bell Potter halves its Syntara valuation   With traditional equity fundraising conditio...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am in the east, once trading kicks...

The S&P ASX 200 Health Care index rose 9.05% in July with rotation into the sector gaining momentum  Lumos soared 170% in July after six-year exclusive deal valued at up to US$317 million with PHASE Scientific for distribution of Febri...

Copper prices crash 20pc Materials sector undercuts market, down 2.57pc Info tech rally not enough to push ASX into positive territory   Tech rally fails to lift resources The ASX staged a steady recovery through the day to finish down ju...

ASX closes trade down 0.11pc Resources only sector on the up, adding 1.82pc Bitcoin smashes new all-time high twice in 24 hours   ASX gives up the ghost in the last hour Despite a valiant struggle back into positive territory by about 2pm...

ASX biotechs target global cell therapy market, projected to reach ~US$48bn by 2034 Arovella the only ASX-listed biotech delving into CAR iNKT therapies and one of few globally Chimeric aims to ‘break new ground’ in treatment of solid tumo...

ASX brushes aside RBA holding rates at 3.85% to close 0.02% higher Global markets feel jitters on US President Donald Trump’s renewed tariff push  First Au enters drill-for-equity deal with Newcam Minerals for Gimlet gold project   The AS...

It was a tale of two halves for the ASX today, and neither were great  Caution abounds ahead of two major market-moving events this week, including RBA and Trump decisions Utilities stock Origin Energy was a big-cap MVP today, although the...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.15am, once trading kicks off in earn...

The ASX 200 Health Care Index fell 1.05% in June and remains the worst performing sector YTD down 6.64% Morgans healthcare analyst Iain Wilkie said June likely saw some tax loss selling before EOFY  Amplia up 300% in June after complete re...

Resources stocks surge; materials sector up 3.02pc ASX 200 Banks fall, shedding 1.3% as finance loses 1.27pc Vietnam inks trade deal with US one week ahead of tariff-pause deadline   ASX wobbles to the finish The ASX 200 was keeping us gu...

Energy sector powers higher again, up more than 5pc ASX uranium stocks surge ASX All Ords Gold index falls almost 5pc While global markets fell on Friday, the ASX has resisted economic riptides, staying afloat to finish up just 1 point or...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10.30am, once trading kicks off in earn...

Despite a strong start, the ASX has paired back gains to finish down 2.9 points or 0.03pc Weakness came from the Health Care sector and gold stocks Info Tech sector rides semiconductor fever higher, up 0.71pc Despite a strong start to the...

The S&P/ASX 200 Health Care Index rose 1.59% in May but remains worst performing sector YTD down 5.65% Morgans healthcare analyst Iain Wilkie said US President Donald Trump’s trade and health policies continue to impact sector Lumos up...

Australia’s S&P/ASX 200 rallied 4.20% in May along with global markets as US-tariff tensions eased All of 11 sectors gained in May, led by tech up almost 20% followed by energy and communication services  Dateline Resources surged 978%...

ASX climbs 0.3pc Gold stocks surge, up almost 2pc Retail sales soften, increasing chance of RBA rate cut The Australian share market worked hard for its gains today, seesawing between negative and positive territory before making a convin...

ASX falls as profit taking cuts banking stocks Energy sector booms on WDS project green light CPI comes in at 2.4pc vs expectations of 2.3pc   A trend of profit taking in the larger banking stocks has pushed the ASX lower by -0.13%, erasi...

Arovella is one of only a handful of biotechs pursuing CAR-iNKT immunotherapies – and is the only ASX-listed exemplar The “soldiers of the blood stream”, CAR-iNKT cells offer potential advantages including easier off-the-shelf therapies Th...

Peter MacCallum Cancer Centre is Australia’s only public hospital dedicated to cancer care, research and education It is home to Australia’s only biomedical facility capable of manufacturing CAR T-cells and other cell therapies at commerci...

ASX jumped 0.5pc just before midday but pared back to just 0.03pc US-China trade negotiation announcement due this evening Energy sector once again leads gains as Healthcare falls   While the first word out of the US-China trade negotiati...

Highlights asx 200 lifted in early trade following gains on the Nasdaq, with support from sectors including Healthcare, Financials, and Energy Dateline Resources (ASX:DTR) saw early activity following US developments on its rare...

ASX falls almost 1pc on Monday after setting new 20-day high last week Sectors in the red right across the board Falling oil price weighs heavily on Energy sector, down more than 2.8pc   An eighth day of gains just wasn’t to be for the AS...

The S&P/ASX 200 Health Care Index rose 2.16% in April with the S&P/ASX 200 rallying 3.6% Morgans healthcare analyst Iain Wilkie said April was a marked improvement on recent months Several approvals during April, including for EBR...

ASX has gained to cinch seventh straight session in the green 10 of 11 sectors on the up Bank index lifts 1.6pc as CBA hits record new share price high The ASX is on trajectory to return to pre-trade war highs after lifting for a seventh...

Morning, and welcome to Stockhead’s Top 10 (at 11… ish), highlighting the movers and shakers on the ASX in early-doors trading. With the market opening at 10am sharp eastern time, the data is taken at 10:15, once trading kicks off in earnes...

ASX recovers from early dip to post 0.24pc gain Tech stocks surge with sector up 4pc Energy and Materials weigh on gains, down more than 1pc each An after-hours surge in US tech stocks has lit the Aussie tech sector on fire, rocketing up...

AdAlta (ASX:1AD) has announced aims to raise up to $1.3 million in a renounceable rights issue to advance its East to West cellular immunotherapy strategy.  Eligible shareholders can apply for two new shares for every three held at $0.03 pe...

Energy and Tech sectors up about 1.5pc each Technology index boosted 1.26pc Materials the only laggard, down 0.59pc While a late run of bears has taken some of the wind out of the ASX’s sails, the Aussie market is firmly in the green toda...

AdAlta subsidiary AdCella brings cutting-edge cellular immunotherapies from Asia – particularly China – into Western markets AdCella has backing of SYNthesis BioVentures Fund, which invests in therapeutics development The biotech fund beli...

Stockhead’s health and biotech expert Tim Boreham is back in the studio for another instalment of the Health Kick Podcast. In this episode, Tim chats with AdAlta (ASX:1AD) CEO and managing director Dr Tim Oldham. For several years, AdAlta...

Australia’s S&P/ASX 200 records its first back-to-back monthly fall since October 2023, down 3.39% in March Ten out 11 S&P/ASX 200 sectors posted losses with utilities the only sector in the black, up 1.52% Metal Powder Works rises...

ASX rebounds 1pc with tech and real estate leading the way Nanosonics jumps  after FDA gives approval Aussie job numbers dip, fuelling rate cut hopes   The ASX had a cracker of a session on Thursday, up by 1.2% as it registered the best o...

AdAlta (ASX:1AD) has built on a deal with SYNthesis BioVentures Fund One, which plans to invest $500,000 in seed funding for its subsidiary AdCella, with a total commitment of up to $2 million. It means AdCella now won’t rely on further cap...

ASX rises on global optimism and China boost Energy and miners shine, Mineral Resources jumps after upgrade Copper hits five-month high, gold edges up   The ASX kicked off the week with a 0.75% bump as global sentiment surged. Today’s reb...

Highlights Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease with limited treatment options. AdAlta, Cynata, and Amplia are advancing innovative therapeutic approaches. Australian biotechnology companies are expanding...

Idiopathic pulmonary fibrosis is a life-threatening lung disease AdAlta’s lead candidate AD-214 is a first-in-class molecule designed to treat IPF Amplia and Cynata therapies also show promise in treating the disease, which has limited tre...

ASX dips as traders weigh China’s stimulus against Trump’s tariffs Miners soften blow but insurance stocks still taking hits Trump gives speech to Congress, here’s what he said…   The ASX had a bit of a ride on Wednesday, with a sharp dip...

The S&P/ASX 200 Health Care Index fell 7.66% in February with the S&P/ASX 200 down 3.79% Morgans healthcare analyst Iain Wilkie said several factors caused investor jitters in February including job cuts to US FDA  Pacific Edge was...

Stockhead’s Fraser Palamara chats withAdAlta (ASX:1AD) managing director Tim Oldham to get the short end of the long story on the company’s latest news. The company announced it’s prioritising its East to West strategy in a bid to to gain a...

AdAlta prioritising East to West cellular immunotherapy strategy  Company now has three products in exclusive due diligence after executing two non-binding term sheets Strategy expected to allow for value realisation in relatively short ti...

AdAlta (ASX:1AD) has unveiled a new grand plan to take cell therapy candidates from Southeast Asia, firm them up in Australian early-stage tests, and then licence those products if successful to European and American markets. But shareho...

Tony Locantro has been a client advisor/investment manager in the stockbroking industry since 1998. He’s focused on the small cap and emerging companies with a strong interest in identifying those in the mining, biotech and industrial secto...

The S&P/ASX 200 Health Care Index fell 1.85% in December but rose 7.51% overall in 2024  Mesoblast surged 52% in December after the US FDA approved its cell therapy Ryoncil for treatment of paediatric GvHD Percheron plunged 91% in Dece...

ASX 200 lifts on tech rally, miners struggle Barrick Gold threatens Mali shutdown over shipping restrictions Bitcoin bounces back after recent slump   The ASX 200 index crept up 0.34% on Tuesday, thanks to a rally in tech following the Na...

The S&P/ASX 200 Health Care Index rose 2.89% in November as momentum returned to the sector Health cryogenic services company Vitrafy and nerve-repair biotech Renerve debuted on the ASX  Paradigm Biopharmaceuticals rose 151% in Novembe...

What is idiopathic pulmonary fibrosis (IPF)? What’s it like living with it? And what treatments are currently available? AdAlta (ASX:1AD) managing director and CEO Dr Tim Oldham joins the Stockhead TV studio to investigate these questions a...

ASX up as mining gains offset tech and bank losses Silex, Paladin and uranium stocks soar on supply squeeze Goldman cuts Aussie GDP forecast as US tariffs loom   After a soft start to the day, the ASX bounced back and closed the day 0.3% ...